BR0113809A - Composições farmacêuticas - Google Patents

Composições farmacêuticas

Info

Publication number
BR0113809A
BR0113809A BR0113809-0A BR0113809A BR0113809A BR 0113809 A BR0113809 A BR 0113809A BR 0113809 A BR0113809 A BR 0113809A BR 0113809 A BR0113809 A BR 0113809A
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical compositions
condition
disorder
cyclooxygenase
Prior art date
Application number
BR0113809-0A
Other languages
English (en)
Inventor
Simon David Bateman
Alberto Gimona
Jurij Holinej
Jasper Huels
Sumedha Jayawardene
Argeris Jerry Karabelas
Maaha Y Khaled
Anees Abdulquadar Karnachi
Eimear Mairin Lochlainn
Richard Macerata
Victor Sloan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0113809A publication Critical patent/BR0113809A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS". Uma composição para tratamento de uma desordem ou condição dependente de ciclooxigenase-2 compreendendo: ácido 5-metil-2-(2'-cloro-6'-flúor anilino) fenil acético ou um sal farmaceuticamente aceitável do mesmo, cuja composição é uma composição farmacêutica de liberação imediata para tratamento da dita desordem ou condição por cerca de 24 horas.
BR0113809-0A 2000-09-11 2001-09-10 Composições farmacêuticas BR0113809A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23165500P 2000-09-11 2000-09-11
US23226100P 2000-09-14 2000-09-14
PCT/EP2001/010448 WO2002020090A2 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0113809A true BR0113809A (pt) 2003-07-29

Family

ID=26925315

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113809-0A BR0113809A (pt) 2000-09-11 2001-09-10 Composições farmacêuticas

Country Status (28)

Country Link
US (2) US20020061932A1 (pt)
EP (1) EP1331972B1 (pt)
JP (2) JP2004527458A (pt)
KR (1) KR20030036730A (pt)
CN (1) CN100490797C (pt)
AR (1) AR030630A1 (pt)
AT (1) ATE366128T1 (pt)
AU (2) AU1390002A (pt)
BR (1) BR0113809A (pt)
CA (1) CA2416771C (pt)
CY (1) CY1107729T1 (pt)
CZ (1) CZ2003673A3 (pt)
DE (1) DE60129238T2 (pt)
DK (1) DK1331972T3 (pt)
ES (1) ES2290181T3 (pt)
HU (1) HUP0301128A3 (pt)
IL (2) IL154238A0 (pt)
MX (1) MXPA03002105A (pt)
MY (1) MY126117A (pt)
NO (1) NO20031095D0 (pt)
NZ (1) NZ524785A (pt)
PE (1) PE20020351A1 (pt)
PL (1) PL359721A1 (pt)
PT (1) PT1331972E (pt)
RU (1) RU2316324C2 (pt)
SI (1) SI1331972T1 (pt)
SK (1) SK2902003A3 (pt)
WO (1) WO2002020090A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
KR20040089654A (ko) * 2002-03-07 2004-10-21 노파르티스 아게 약제학적 조성물
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
RU2423979C2 (ru) * 2005-06-17 2011-07-20 АФТ Фармасьютикалз Лимитед Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
US20080237823A1 (en) * 2007-01-11 2008-10-02 Analog Devices, Inc. Aluminum Based Bonding of Semiconductor Wafers
KR20110055682A (ko) * 2008-08-22 2011-05-25 노파르티스 아게 간독성과 연관된 ｈｌａ 대립형질을 보유하지 않은 환자에서 ｃｏｘ-2 의존성 장애의 치료를 위한 ｃｏｘ-2 억제제의 용도
US8227451B2 (en) 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (zh) * 2013-12-31 2016-05-18 上海复力生物医药科技有限公司 磷虾油的制备方法
CN109906082A (zh) 2016-09-07 2019-06-18 塔夫茨大学信托人 使用免疫dash抑制剂和pge2拮抗剂的组合治疗
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028936A1 (en) * 1993-06-08 1994-12-22 Ciba-Geigy Ag Process for the preparation of an oral solid dosage form containing diclofenac
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SK284330B6 (sk) * 1996-05-17 2005-01-03 Merck & Co., Inc. Použitie 3-fenyl-4-(4-metylsulfonyl)fenyl)-2-(5H)-furanónu
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica

Also Published As

Publication number Publication date
NO20031095L (no) 2003-03-10
MY126117A (en) 2006-09-29
DE60129238T2 (de) 2008-03-06
KR20030036730A (ko) 2003-05-09
CY1107729T1 (el) 2013-04-18
NZ524785A (en) 2005-10-28
US20040186179A1 (en) 2004-09-23
PT1331972E (pt) 2007-10-16
AU2002213900C1 (en) 2006-07-27
CA2416771C (en) 2010-11-02
WO2002020090A9 (en) 2003-10-30
ATE366128T1 (de) 2007-07-15
IL154238A (en) 2008-11-26
SK2902003A3 (en) 2003-10-07
EP1331972A2 (en) 2003-08-06
JP2011144194A (ja) 2011-07-28
PL359721A1 (en) 2004-09-06
WO2002020090A2 (en) 2002-03-14
IL154238A0 (en) 2003-09-17
CN100490797C (zh) 2009-05-27
HUP0301128A2 (hu) 2003-10-28
JP2004527458A (ja) 2004-09-09
SI1331972T1 (sl) 2007-12-31
AU1390002A (en) 2002-03-22
EP1331972B1 (en) 2007-07-04
DE60129238D1 (de) 2007-08-16
CA2416771A1 (en) 2002-03-14
CZ2003673A3 (cs) 2003-06-18
MXPA03002105A (es) 2003-06-19
PE20020351A1 (es) 2002-06-14
AU2002213900B2 (en) 2006-02-16
WO2002020090A3 (en) 2003-05-30
CN1455691A (zh) 2003-11-12
US20020061932A1 (en) 2002-05-23
NO20031095D0 (no) 2003-03-10
RU2316324C2 (ru) 2008-02-10
DK1331972T3 (da) 2007-11-05
HUP0301128A3 (en) 2005-04-28
ES2290181T3 (es) 2008-02-16
AR030630A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
BRPI0409109A (pt) novos compostos
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0413490A (pt) novos compostos
BR9509683A (pt) Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
AP2000001860A0 (en) Hypolipidemic benzothiazepine compounds.
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
BR0010555A (pt) Inibidores de neuraminidases
BR0314302A (pt) Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
BR0206955A (pt) Ligantes de receptores de canabinóides
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
EP2050442A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BONE DISORDERS, FUNCTIONAL FOOD OR HEALTH MEASURES CONTAINING THIS COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AS AN ACTIVE SUBSTANCE
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/196 (2006.01), A61P 5/00 (2006.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]